Aspen Pharmacare Holdings Ltd. will reduce its A$707 million ($596 million) takeover offer for Sigma Pharmaceuticals Ltd. after reviewing the Australian company’s accounts, a person familiar with the matter said.
Patients with heart failure can reduce the risk of further occurrences by as much as 80 percent using an experimental stem-cell treatment, according to a study whose results are among the most promising for such therapies.
Grifols SA , Europe’s largest maker of blood-plasma products, agreed to buy Talecris Biotherapeutics Holdings Corp. for about $3 billion in cash and stock to expand its share to almost a third of the U.S. market.
Cephalon Inc. took a 20 percent stake in Mesoblast Ltd. and bought the rights to market the Australian company’s adult stem-cell therapies for heart and nervous system conditions in a deal potentially worth more than $2 billion.
Talecris Biotherapeutics Holdings Corp. will proceed with an $800 million expansion of its blood- plasma production capacity amid an announced takeover by Grifols SA , Chief Executive Officer Lawrence Stern said.